Pharmalot Ed Silverman STAT Plus: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
Pharmalot Ed Silverman STAT Plus: Pharma wins a key round in a court battle with hospitals over a drug discount program
Pharmalot Ed Silverman STAT Plus: ‘A classic case’: A legal expert explains why lawsuits challenging abortion pill restrictions may succeed
First Opinion Emil D. Kakkis STAT Plus: As it turns 40, the Orphan Drug Act for rare diseases needs a refresh
Pharmalot Ed Silverman STAT Plus: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients
Pharmalot Ed Silverman STAT Plus: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices
Health Andrew Joseph FDA pulls Evusheld authorization as coronavirus evolution quashes another therapy
First Opinion Thomas J. Moore and G. Caleb Alexander A dangerous loophole for drug ads needs to be closed
Pharmalot Ed Silverman STAT Plus: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment
Health Andrew Joseph STAT Plus: They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
Pharmalot Ed Silverman STAT Plus: Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad
First Opinion Stacey McKenna STAT Plus: Making naloxone available over the counter won’t solve the overdose crisis — but it will help
Politics John Wilkerson STAT Plus: The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals
Special Report Rosa Furneaux and Laura Margottini — TBIJ STAT Plus: The drug was meant to save children’s lives. Instead, they’re dying
Pharmalot Ed Silverman STAT Plus: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad
Health Tech Mohana Ravindranath STAT Plus: Amazon Pharmacy expands with new $5 monthly prescription service
Pharmalot Ed Silverman STAT Plus: Many pediatric drug study results were never posted to a U.S. government database
Politics Sarah Owermohle STAT Plus: Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates
Politics Rachel Cohrs STAT Plus: PhRMA terminates lobbying contract with White House official’s brother
Pharmalot Ed Silverman STAT Plus: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity
Pharmalot Ed Silverman STAT Plus: FTC wants ‘pharma bro’ Martin Shkreli held in contempt for violating lifelong ban on working in pharma
Health Elaine Chen STAT Plus: Mix-it-yourself Wegovy? Some are trying risky sources for weight-loss drugs
Pharmalot Ed Silverman STAT Plus: Major purchasers predict expensive new therapies will keep driving drug price hikes
Pharmalot Ed Silverman STAT Plus: Large health insurers lowered barriers to fair access to some drugs, analysis finds
First Opinion Daniel Eisenkraft Klein STAT Plus: Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it
Health Tech Katie Palmer STAT Plus: Telehealth patients are scrambling for in-person care amid crackdown on online controlled substances